Urolithin A alleviates early brain injury after subarachnoid hemorrhage by regulating the AMPK/mTOR pathway-mediated autophagy

Neurochirurgie. 2023 Sep;69(5):101480. doi: 10.1016/j.neuchi.2023.101480. Epub 2023 Aug 19.

Abstract

Objective: Unfavorable outcomes in patients with subarachnoid hemorrhage (SAH) are mainly attributed to early brain injury (EBI). Reduction of neuronal death can improve the prognosis in SAH patients. Autophagy and apoptosis are critical players in neuronal death. Urolithin A (UA) is a natural compound produced by gut bacteria from ingested ellagitannins and ellagic acid. Here, we detected the role of UA in EBI post-SAH.

Methods: We established an animal model of SAH in rats by endovascular perforation, with administration of UA, 3-methyladenine (3-MA) and Compound C. SAH grading, neurological function, brain water content, western blotting analysis of levels of proteins related to apoptosis, autophagy and pathways, blood-brain barrier (BBB) integrity, TUNEL staining, and immunofluorescence staining of LC3 were evaluated at 24h after SAH.

Results: SAH induction led to neurological dysfunctions, BBB disruption, and cerebral edema at 24h post-SAH in rats, which were relieved by UA. Additionally, cortical neuronal apoptosis in SAH rats was also attenuated by UA. Moreover, UA restored autophagy level in SAH rats. Mechanistically, UA activated the AMPK/mTOR pathway. Furthermore, inhibition of autophagy and AMPK limited UA-mediated protection against EBI post-SAH CONCLUSION: UA alleviates neurological deficits, BBB permeability, and cerebral edema by inhibiting cortical neuronal apoptosis through regulating the AMPK/mTOR pathway-dependent autophagy in rats following SAH.

Keywords: AMPK/mTOR; Autophagy; Early brain injury; Subarachnoid hemorrhage; Urolithin A.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Autophagy / physiology
  • Brain Edema* / drug therapy
  • Brain Edema* / etiology
  • Brain Injuries* / drug therapy
  • Humans
  • Rats
  • Rats, Sprague-Dawley
  • Subarachnoid Hemorrhage* / drug therapy
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • AMP-Activated Protein Kinases
  • 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one
  • TOR Serine-Threonine Kinases
  • mTOR protein, rat